Kenosha kicked off its 175th year with a celebration recalling its unique history, trivia, quirks, resilience and renaissance ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

Following a second day of stock market gains, investors looked forward to earnings reports from Eli Lilly and Amazon.

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... have a complex performance history. Since their inception in 1949, hedge funds have evolved significantly ...

Indeed, the company's pipeline is impressive overall. What to Expect From Blockbuster GLP-1 Treatments Much of Eli Lilly's momentum in recent quarters has been due to Mounjaro and Zepbound.

Novo Nordisk and Eli Lilly have filed a motion to dismiss in the MDL over Ozempic and similar drugs. The defendants are asking the court to throw out 12 of the plaintiffs' 17 claims. The ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...